Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

Approval of Nucala marks the first biologic approved for chronic obstructive pulmonary disease patients with blood eosinophil ...

The U.S. Food and Drug Administration has approved GSK's Nucala (mepolizumab) as an add-on maintenance treatment for adult ...

While not the first biologic to break into the COPD sector – Sanofi and Regeneron took that crown with the approval of their ...

GSK respiratory, immunology and inflammation research and development (R&D) global head and senior vice-president Kaivan ...

The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe ...

Berenberg has lowered its rating on GSK plc (LON: GSK) to Hold from Buy, a move driven by the stock’s strong year-to-date ...

On May 18, at the 2025 American Thoracic Society (ATS) International Conference, updated findings from a post hoc analysis poster presentation of the Phase III MATINEE trial (NCT04133909) reinforced ...

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

London: GSK plc has received approval from the US Food and Drug Administration (FDA) for Nucala (mepolizumab) as an add-on ...